[Department Circular No. 2023-0061] Health Technology Assessment Council (HTAC) Recommendation for the Inclusion of Filgrastim 300 mcg/0.9 mL Solution (IV, SC), 0.9 mL Pre-filled Syringe for the Treatment of Neutropenia in Patients Undergoing Bone Marrow Transplantation and Patients Receiving Myelosuppressive Cancer Chemotherapy in the Philippine National Formulary (PNF) Posted on February 13, 2023
[DC No. 2023-0060] Health Technology Assessment Council (HTAC) Recommendation for the Inclusion of Recombinant Human Erythropoietin (Epoetin Alfa) 4000 IU/mL Solution for Injection (IV/SC) 1mL Pre-filled Syringe for the Management of Chemotherapy-Induced Anemia in Patients with Non-Myeloid Disease in the Philippine National Formulary (PNF) Posted on February 13, 2023
[Advisory] Extension of the Call for Nominations to the Health Technology Assessment Council (HTAC) Core Committee and Subcommittee Members until 27 January 2023 Posted on December 22, 2022
[Department Circular No. 2022 – 0625] Health Technology Assessment Council (HTAC) Recommendation for the Inclusion of Abiraterone Acetate and Non-Inclusion of Enzalutamide for Individuals with Metastatic Castration-Resistant Prostate Cancer in the Philippine National Formulary (PNF) Posted on December 15, 2022
[Department Memorandum No. 2022 – 0545] Interim Guidelines on the Process and Methods for the Selection of Medical Devices for Inclusion in the Philippine Essential Medical Device List (PEMDL) Posted on December 14, 2022
